X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (606) 606
Publication (53) 53
Book Review (15) 15
Book Chapter (6) 6
Data Set (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
trabectedin (586) 586
humans (357) 357
oncology (353) 353
index medicus (349) 349
chemotherapy (227) 227
female (205) 205
sarcoma (161) 161
cancer (157) 157
middle aged (139) 139
adult (125) 125
dioxoles - therapeutic use (120) 120
male (120) 120
tetrahydroisoquinolines - therapeutic use (112) 112
aged (110) 110
pharmacology & pharmacy (109) 109
antineoplastic agents, alkylating - therapeutic use (104) 104
et-743 (98) 98
ecteinascidin-743 (97) 97
phase-ii (94) 94
ovarian cancer (92) 92
sarcoma - drug therapy (89) 89
animals (88) 88
dioxoles - administration & dosage (88) 88
soft-tissue sarcoma (87) 87
tetrahydroisoquinolines - administration & dosage (87) 87
dioxoles - adverse effects (85) 85
soft tissue sarcoma (80) 80
tetrahydroisoquinolines - adverse effects (79) 79
research (76) 76
pegylated liposomal doxorubicin (74) 74
care and treatment (73) 73
doxorubicin (73) 73
treatment outcome (73) 73
dioxoles - pharmacology (72) 72
tumors (68) 68
drug therapy (67) 67
antitumor-activity (66) 66
disease-free survival (65) 65
leiomyosarcoma (63) 63
liposarcoma (61) 61
antineoplastic agents, alkylating - adverse effects (60) 60
medicine & public health (60) 60
tetrahydroisoquinolines - pharmacology (59) 59
antineoplastic combined chemotherapy protocols - therapeutic use (58) 58
metastasis (57) 57
ovarian neoplasms - drug therapy (57) 57
ifosfamide (53) 53
analysis (52) 52
tetrahydroisoquinolines (52) 52
antineoplastic agents, alkylating - pharmacology (51) 51
soft-tissue sarcomas (51) 51
sarcoma - pathology (49) 49
efficacy (48) 48
cancer therapies (47) 47
clinical trials (47) 47
gemcitabine (47) 47
neoplasms - drug therapy (46) 46
patients (46) 46
young adult (46) 46
aged, 80 and over (42) 42
antineoplastic agents - therapeutic use (42) 42
retrospective studies (42) 42
safety (42) 42
trial (42) 42
hematology, oncology and palliative medicine (41) 41
pharmacology/toxicology (40) 40
antineoplastic agents, alkylating - administration & dosage (39) 39
homologous recombination (38) 38
cell line, tumor (37) 37
dioxoles - pharmacokinetics (37) 37
doxorubicin - administration & dosage (37) 37
mice (37) 37
yondelis (37) 37
therapy (36) 36
randomized phase-ii (35) 35
dna (34) 34
toxicity (34) 34
apoptosis (33) 33
european organization (33) 33
neoplasms. tumors. oncology. including cancer and carcinogens (33) 33
solid tumors (33) 33
tetrahydroisoquinolines - pharmacokinetics (33) 33
health aspects (32) 32
antineoplastic agents - pharmacology (31) 31
cancer research (31) 31
dna repair (31) 31
ecteinascidin-743 et-743 (31) 31
metastatic liposarcoma (31) 31
obstetrics & gynecology (31) 31
survival (31) 31
adolescent (30) 30
anthracyclines (30) 30
antitumor (30) 30
deoxyribonucleic acid--dna (30) 30
leiomyosarcoma - drug therapy (30) 30
mechanism (29) 29
docetaxel (28) 28
doxorubicin - analogs & derivatives (28) 28
prognosis (28) 28
continuous intravenous-infusion (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (580) 580
French (8) 8
German (6) 6
Spanish (5) 5
Polish (4) 4
Russian (4) 4
Japanese (3) 3
Chinese (1) 1
Czech (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2018, Volume 36, Issue 31, pp. 3134 - 3134
PurposeThis multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients... 
TRABECTEDIN | ONCOLOGY | PM01183 | DNA | ORIGINAL REPORTS
Journal Article
The Oncologist, ISSN 1083-7159, 01/2018, Volume 23, Issue 1, pp. 62 - 70
Because of the rarity of alveolar soft part sarcoma and the lack of prospective trials, a retrospective, multi‐institutional, caseseries analysis was conducted... 
Chemotherapy | Sarcoma | Trabectedin | Alveolar soft part sarcoma | Pazopanib | SOLID TUMORS | EFFICACY | TISSUE SARCOMA | PHASE-II | ANTITUMOR-ACTIVITY | METASTATIC LIPOSARCOMA | ONCOLOGY | SUNITINIB | MUSCULOSKELETAL ONCOLOGY GROUP | TUMOR MICROENVIRONMENT | Sarcomas
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2018, Volume 29, Issue 9, pp. 1995 - 2002
Abstract Background Treatment options for soft tissue sarcoma (STS) patients aged ≥65 years (elderly) can be limited by concerns regarding the increased risk... 
soft tissue sarcomas | elderly | trabectedin | Original
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 06/2017, Volume 44, Issue 6, pp. 463 - 467
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 28, pp. 19929 - 19944
Therapy-induced senescence is a major cellular response to chemotherapy in solid tumors. Senescent tumor cells acquire a secretory phenotype, or SASP, and... 
Therapy-induced senescence | NF-kappaB | Trabectedin | SASP | Apoptosis
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 01/2019, Volume 72, pp. 37 - 44
Journal Article
Nowotwory, ISSN 0029-540X, 11/2018, Volume 68, Issue 3, pp. 127 - 131
Journal Article
01/2010
Soft tissue sarcomas (STSs) are rare and histologically diverse neoplasms. Recent results of various meta-analyses and development of newer drugs have changed... 
neoadjuvant | Chemotherapy | metastatic STSs | adjuvant | IGF inhibitors | trabectedin | mTOR inhibitors | soft tissue sarcoma | VEGF inhibitors
Web Resource
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ISSN 0006-291X, 05/2019, Volume 513, Issue 2, pp. 326 - 331
Recurrent osteosarcoma is a chemotherapy-resistant disease. Individualized precision therapy is needed for this disease. Toward this goal, we have developed... 
Irinotecan | BIOPHYSICS | MECHANISM | Osteosarcoma | Patient-derived othotopic xenograft | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOXORUBICIN | PDOX | Trabectedin | Combination therapy | CELL
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2018, Volume 119, Issue 5, pp. 565 - 571
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 09/2018, Volume 29, Issue 9, pp. 1995 - 2002
Background: Treatment options for soft tissue sarcoma (STS) patients aged >= 65 years (elderly) can be limited by concerns regarding the increased risk of... 
soft tissue sarcomas | SAFETY | elderly | DOXORUBICIN | IFOSFAMIDE | FAILURE | TRIAL | METASTATIC LIPOSARCOMA | ONCOLOGY | trabectedin | SOFT-TISSUE SARCOMA | AGE | SCHEDULES
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2018, Volume 24, Issue 21, pp. 5233 - 5238
Purpose: The prognosis for patients with refractory softtissue sarcoma (STS) is dismal. Anlotinib has previously shown antitumor activity on STS in preclinical... 
DOXORUBICIN-BASED CHEMOTHERAPY | 1ST-LINE TREATMENT | LIPOSARCOMA | ONCOLOGY | 2-STAGE DESIGNS | CLINICAL-TRIALS | DOUBLE-BLIND | CONTROLLED PHASE-3 TRIAL | OPEN-LABEL | TRABECTEDIN | PART SARCOMA
Journal Article
Expert Opinion on Therapeutic Targets, ISSN 1472-8222, 08/2019, Volume 23, Issue 8, pp. 651 - 654
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2018, Volume 19, Issue 10, pp. 1269 - 1270
Journal Article
Journal Article